Böhmer D, Wenz F, Martin T, Sedlmayr F, Hinkelbein W, Wiegel T
Klinik für Strahlentherapie, Charité-Universitätsmedizin Berlin, Campus-Virchow-Klinikum, Augustenburger Platz 1, 13353 Berlin.
Urologe A. 2010 Feb;49(2):211-5. doi: 10.1007/s00120-010-2241-8.
Radiation therapy is a treatment option for curative management of localized and locally advanced prostate cancer. Depending on tumor stage and constellation of risk factors (PSA level, findings on digital rectal examination, and Gleason score), various forms of radiotherapy are applied. In addition to the sole use of external beam radiotherapy, brachytherapy with radioactive seeds is also employed as stand-alone treatment in patients with low risk factors and in early clinical stages. Increasing risk of recurrence requires more intensive therapies which can be accomplished by adding hormone deprivation therapy and/or intensifying radiation therapy (dose escalation). Combined approaches using brachytherapy and percutaneous radiotherapy are also initiated in these cases. If hormone ablation therapy is administered, this should occur over a course of 3-36 months as neoadjuvant, concommitant and/or adjuvant treatment, depending on the risk of recurrence.
放射治疗是局限性和局部晚期前列腺癌根治性治疗的一种选择。根据肿瘤分期和风险因素组合（前列腺特异抗原水平、直肠指检结果和 Gleason 评分），应用各种形式的放射治疗。除了单独使用外照射放疗外，对于低风险因素和临床早期的患者，放射性粒子近距离放疗也可作为独立治疗方法。复发风险增加需要更强化的治疗，这可通过添加激素剥夺治疗和/或强化放射治疗（剂量递增）来实现。在这些情况下，也会启动使用近距离放疗和经皮放疗的联合方法。如果进行激素消融治疗，应根据复发风险，作为新辅助、同步和/或辅助治疗，在 3 - 36 个月的疗程内进行。
